PureTech Health plc (PRTC) Stock Score, Valuation & Financial Research
PureTech Health plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 25/100.
Quick answer for PRTC
PureTech Health plc currently has a Wall Street Score of 25/100. The stored market price is $17.38. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -5.0 points. These figures are a research snapshot, not a buy or sell recommendation.
What PureTech Health plc does
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the
PRTC financial snapshot
- Wall Street Score:
- 25/100
- Current price:
- $17.38
- Market capitalization:
- $4.23B
- Revenue:
- $9.0M
- Net income:
- $-56.0M
- Free cash flow:
- $-85.3M
- Cash:
- $254.1M
- Total debt:
- $19.6M
- EPS:
- -26.80
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 35/100
What stands out
- Reported year-over-year revenue growth is +0.9%.
- Free cash flow is $-85.3M, showing cash burn in the current stored period.
- The balance sheet shows $254.1M of cash versus $19.6M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -5.0 points: PRTC decreased 5 points because Asset declined by 31.4 points, Capital declined by 27 points, Buffett declined by 4.7 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research PRTC
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.